<- Go Home
Sirtex Medical Pty Ltd.
Sirtex Medical Pty Ltd manufactures and distributes liver cancer treatments utilizing small particle technology in North America, Australia, New Zealand, Asia, Europe, and Latin America. The company offers SIR-Spheres Y-90 resin microspheres, a targeted radioactive treatment for primary and secondary metastatic liver cancer. It also offers SIROS, a drug delivery system. The company was incorporated in 1997 and is based in Sydney, Australia. As of September 20, 2018, Sirtex Medical Pty Ltd. operates as a subsidiary of CDH Genetech Limited.
Market Cap
AUD 1.9B
Volume
475.8K
Cash and Equivalents
AUD 69.9M
EBITDA
AUD 60.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 181.2M
Profit Margin
82.82%
52 Week High
AUD 33.58
52 Week Low
AUD 13.33
Dividend
N/A
Price / Book Value
11.76
Price / Earnings
45.96
Price / Tangible Book Value
12.40
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
AUD 57.9M
Return on Equity
26.87%
Return on Assets
17.24
Cash and Short Term Investments
AUD 127.9M
Debt
N/A
Equity
AUD 159.2M
Revenue
AUD 218.7M
Unlevered FCF
AUD 51.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium